S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
OTCMKTS:QBIO

Q BioMed (QBIO) Stock Forecast, Price & News

$0.11
-0.04 (-26.67%)
(As of 05/13/2022 03:47 PM ET)
Add
Compare
Today's Range
$0.11
$0.14
50-Day Range
$0.11
$0.31
52-Week Range
$0.11
$1.06
Volume
162,100 shs
Average Volume
120,032 shs
Market Capitalization
$3.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.43
30 days | 90 days | 365 days | Advanced Chart
Receive QBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Q BioMed and its competitors with MarketBeat's FREE daily newsletter.

Q BioMed logo

About Q BioMed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

Headlines

Q BioMed Inc (QBIO)
Q BioMed (OTCMKTS:QBIO) Shares Down 8.9%
Q BioMed outlines strategic direction and goals for 2022
Q BioMed Outlines Strategic Direction for 2022
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:QBIO
Previous Symbol
NASDAQ:QBIO
Fax
N/A
Employees
3
Year Founded
N/A

Sales & Book Value

Annual Sales
$200 thousand
Book Value
($0.37) per share

Profitability

Net Income
$-8.24 million
Net Margins
-2,971.96%
Pretax Margin
-2,972.32%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$3.84 million
Optionable
Not Optionable

Company Calendar

Last Earnings
4/14/2022
Today
5/16/2022
Fiscal Year End
11/30/2022

MarketRank

Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Q BioMed (OTCMKTS:QBIO) Frequently Asked Questions

Are investors shorting Q BioMed?

Q BioMed saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 3,600 shares, a decline of 91.5% from the April 15th total of 42,600 shares. Based on an average trading volume of 602,300 shares, the short-interest ratio is currently 0.0 days.
View Q BioMed's Short Interest
.

How were Q BioMed's earnings last quarter?

Q BioMed Inc. (OTCMKTS:QBIO) announced its earnings results on Thursday, April, 14th. The company reported ($0.08) earnings per share for the quarter. The firm earned $0.08 million during the quarter.
View Q BioMed's earnings history
.

Who are Q BioMed's key executives?
Q BioMed's management team includes the following people:
  • Mr. Denis D. Corin, Chairman, CEO & Pres (Age 49, Pay $300k)
  • Mr. William S. Rosenstadt, Chief Legal Officer, Gen. Counsel & Director (Age 54, Pay $300k)
  • Mr. David Laskow-Pooley, VP of Product Devel. (Age 68)
  • Mr. Robert Derham, VP of Orphan Products
  • Mr. Ari Jatwes, Bus. Devel. Analyst
  • Dr. Amy Ripka, Medicinal Chemistry Advisor
What other stocks do shareholders of Q BioMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Q BioMed investors own include NVIDIA (NVDA), Micron Technology (MU), Washington Trust Bancorp (WASH), Nokia Oyj (NOK), (CGC), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Intel (INTC), OPKO Health (OPK) and AT&T (T).

What is Q BioMed's stock symbol?

Q BioMed trades on the OTCMKTS under the ticker symbol "QBIO."

How do I buy shares of Q BioMed?

Shares of QBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Q BioMed's stock price today?

One share of QBIO stock can currently be purchased for approximately $0.11.

How much money does Q BioMed make?

Q BioMed has a market capitalization of $3.84 million and generates $200 thousand in revenue each year. The company earns $-8.24 million in net income (profit) each year or ($0.310010) on an earnings per share basis.

How many employees does Q BioMed have?

Q BioMed employs 3 workers across the globe.

What is Q BioMed's official website?

The official website for Q BioMed is www.qbiomed.com.

How can I contact Q BioMed?

Q BioMed's mailing address is 366 MADISON AVENUE 3RD FLOOR, NEW YORK NY, 10017. The company can be reached via phone at (646) 889-2226.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.